An open-labelled, prospective clinical study to evaluate effect of Prostate24 in benign prostatic hyperplasia male human patients

Institute of Pharmacy Nirma University0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

研究概览

暂无简介。

•i.Age above 45 years
•ii.Male participants diagnosed with BPH
•iii.Participant must not have taken any drug/ vitamin/ mineral/ dietary or herbal supplements for BPH 1 month prior to enrolment in the study and agrees to not use any new vitamins and/or minerals and/or dietary and/or herbal supplements until after study completion.
•iv.Participant must be able, willing and likely to fully comply with study procedures and restrictions.
•v.Participant willing to sign the informed consent

•i.Evidence of renal disease (S. Creatinine > 1.5mg/ml)
•ii.Evidence of liver disease (AST/ALT >3 times of normal)
•iii.History of alcohol intake and smoking.
•iv.Participation in any other clinical trial with in the last 30 days
•v.History of intake of diuretics, Finasteride like drugs or dietary supplements for the treatment of BPH
•vi.History of intolerance or hypersensitivity to any of the content of the study drug
•vii.Any condition which in the opinion of the PI that is significant and can make the subject unsuitable for study or can place it under additional risk, such as intolerance, allergy to study drug, etc

发起方

Institute of Pharmacy Nirma University